| 39.06 -1.53 (-3.77%) | 04-05 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Colfax Corporation operates as a global, diversified technology enterprise, structured into two primary divisions: Fabrication Technology and Medical Technology. The Fabrication Technology division specializes in the formulation, development, manufacturing, and supply of consumable products and associated equipment. These are crucial for industrial applications such as cutting, joining, automated welding, and gas flow control. Its comprehensive product portfolio includes a variety of welding consumables, like electrodes, wires, and fluxes, alongside cutting consumables such as nozzles, shields, and tips. These items are distributed through independent channels and direct sales to diverse markets, including general industry, construction, infrastructure, transportation, energy, and medical and life sciences, predominantly under the ESAB brand. Conversely, the Medical Technology division is dedicated to the development, production, and distribution of advanced medical devices. These devices are utilized by a broad spectrum of healthcare practitioners, including orthopedic specialists, surgeons, physical therapists, and athletic trainers, to manage musculoskeletal conditions caused by degenerative diseases, deformities, traumatic incidents, and sports-related injuries. Its extensive product offerings encompass rigid and soft orthopedic bracing, hot and cold therapy systems, bone growth stimulators, vascular therapy solutions, therapeutic footwear, electrical stimulators for pain management, and a full range of reconstructive joint implants for areas like the hip, knee, and shoulder. Sales for this segment, primarily under the DJO brand, occur via independent distributors (such as healthcare professionals and retail pharmacies) and direct channels. Established in 1860, Colfax Corporation is headquartered in Wilmington, Delaware.
Mon, 28 Mar 2022
Colfax Announces Board of Directors for Post-Spinoff ESAB - GlobeNewswire
Mon, 14 Mar 2022
Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Off of ESAB Corporation - GlobeNewswire
Sat, 30 Oct 2021
Starboard Value spots fresh opportunities for diversified tech company Colfax - CNBC
Tue, 31 Aug 2021
DJO® Introduces New EMPOWR Dual Mobility™ Hip System at AAOS - Nasdaq
Wed, 28 Jul 2021
Colfax Announces Pricing of Secondary Offering of 6,544,522 Shares of Common Stock - GlobeNewswire
Tue, 30 Mar 2021
DJO Invests in Next-Generation Augmented Reality Technology Primed for ASC Market Growth - businesswire.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Industrials
|
|
|
Industry:
Industrial - Machinery
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|